医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Preceptis Medical Announces Series B Financing and Global Growth Strategy for China

2017年11月22日 AM08:20
このエントリーをはてなブックマークに追加


 

MINNEAPOLIS

Preceptis Medical, Inc., manufacturer of the Hummingbird TTS (Tympanostomy Tube System) technology that enables a conscious sedation alternative to general anesthesia for placing ear tubes in children, today announced the successful initial closing of a Series B financing led by a group of Chinese private investors. This Series B financing will allow Preceptis to expand its commercial infrastructure and develop future pipeline technologies. In addition, the new partners from China will assist Preceptis in accelerating global expansion by bringing its cutting edge technology to China. Mr. JC Sun served as the strategic advisor for the overall partnership and strategic planning.

Ear tube procedures are the most common pediatric procedure in the U.S. (1.2M cases per year) and are currently performed in children using general anesthesia — the only option until now. The Hummingbird TTS is the only product that has received FDA clearance for ear tube procedures using conscious sedation; giving anesthesiologists the ability to adjust the level of sedation needed for this quick, minor procedure. “The Hummingbird TTS has demonstrated its safety and efficacy in U.S. clinical trials and pilot commercial use. Parents and pediatricians have already shown that they will seek out otolaryngologists and hospitals that offer the Hummingbird TTS for ear tube procedures. The next step is a full commercial release in the US, followed by China and the rest of the world,” said Steve Anderson, CEO of Preceptis Medical, Inc.

About Preceptis Medical, Inc.

Preceptis Medical manufactures pediatric surgical technologies designed especially for the unique needs of children and the medical professionals that care for them. Its first product, the Hummingbird TTS, provides the first and only FDA cleared ear tube solution that doesn’t require general anesthesia in young children, reduces healthcare costs by enabling the procedure to be performed out of the O.R. and allows added convenience for families and their children. Annually, there are 1.2 million ear tube procedures in the U.S. in young children and millions of similar procedures worldwide.

For additional information, log onto https://www.facebook.com/preceptismedical or the Company’s website, www.preceptismedical.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171121006163/en/

CONTACT

Preceptis Medical, Inc.
Carla Dahl, 952-250-3275
carla@preceptismedical.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Scientist.comがインク誌から「米国内で最も急成長中の非公開企業」のトップ10に指名される
  • Urban Drinking Water Challenge 2018 Announces Winners from USA, India and Bangladesh
  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement